Allergic Rhinitis - Pipeline Assessment and Market Forecasts to 2017

23 Jul 2010 • by Natalie Aster

GlobalData, the industry analysis specialist, has released a new report, “Allergic Rhinitis - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global allergic rhinitis market. The report identifies the key trends shaping and driving the global allergic rhinitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to significantly shift the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global allergic rhinitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

The Allergic Rhinitis Therapeutics Market is Estimated to Shrink at a CAGR of 3.2% from 2009 to 2017

The global allergic rhinitis therapeutics market was valued at $6.9 billion in 2009 and is forecast to decline by 3.2% annually for the next eight years to reach $5.4 billion in 2017. The decline in market size is primarily due to strong competition and the entry of low cost drugs into the market. Although the disease incidence rate and prescription rate are increasing year on year, declining drug prices will cause the market to shrink.

Highly Competitive Allergic Rhinitis Market Consists of 10 Approved Drugs and a Few Generic Drugs

Medpointe Pharmaceutical, GlaxoSmithKline (GSK), Merck & Co, and AstraZeneca are the leading competitors in the global allergic rhinitis market. The competitive landscape is highly populated with 10 products, six of which can be described as strong. This market is characterized by high levels of self medication.

Weak Pipeline is Expected to Produce Similar Drugs

Approximately 61 products were in different developmental stages in 2009. Bilastine, Sublivac, Donase (Azelastine+Fluticasone) and GSK256066 are the key products currently in the pipeline. Bilastine, Donase and GSK256066 are me-too drugs that are either H1 antagonists or corticosteroids. In addition, the pipeline consists of drugs that are extracts of allergens capable of inducing an immunological response and monoclonal antibodies that are very specific to the suppression of the IgE protein that is found in elevated levels in the blood during allergic rhinitis.

Current Treatment Options Cater to Most of the Market Needs

At present the allergic rhinitis market is highly competitive with 10 approved drugs and three generics. The dominant classes of drugs are H1 or histamine antagonists and anti-inflammatory corticosteroids. The various formulations of the above classes of drugs such as nasal sprays, tablets, capsules or aqueous suspensions serve almost all the market opportunities. The current treatment options are capable of serving the infant sector as well. At present the drugs are capable of inducing a response within eight hours after the medication. However, any new entrant that has a better response rate will capture value in the market.

About GlobalData

GlobalData is an industry analysis specialist company providing business information products and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.